Articles tagged "Kidney transplantation"

2022 American Transplant Congress
Low Fixed Tacrolimus Starting Dose and the Correlation with Renal Allograft Rejection
R. Davoudi, E. Kitchel, S. Lee, T. Tan, T. Sievers, S. Bunnapradist
David Geffen School of Medicine, Los Angeles, CA
*Purpose: Achieving a tacrolimus therapeutic trough concentration (C0) by post-operative day (POD) 3-7 has been associated with a reduced risk for rejection. Although FDA prescribing…
2022 American Transplant Congress
Real World Experience Utilizing Donor Kidneys at Risk for Acute Kidney Injury with Belatacept Based Maintenance Immunosuppression
B. Sirandas, A. Chan, M. Eiting, T. Larson, C. Truax, L. Smith
University of Utah Health, Salt Lake City, UT
*Purpose: The demand for kidney transplant continues to rise, and limited supply has encouraged acceptance of marginal donor organs, such as those at risk for…
2022 American Transplant Congress
Patient Reported Outcomes Following Renal Transplantation: The Future of Holistic Post-Transplant Care
H. V. Spiers¹, S. Frame², R. Heape³, K. Clark², A. Altinar², L. Ross², H. Wells², A. Simpson³, J. Chilcot³, L. Hughes³, D. M. Summers¹, J. Weinman³, M. Hotopf³, A. J. Cronin²
¹Roy Calne Transplant Unit, Department of Transplantation, Addenbrooke's Hospital, Cambridge, United Kingdom, ²Department of Nephrology and Transplantation, Guy’s and St. Thomas’ Hospital, London, United Kingdom, ³King's College London, London, United Kingdom
*Purpose: Patients with renal disease prioritise symptoms and functionality over the biochemistry and clinical guidelines, which clinicians traditionally rely on. Whilst kidney transplantation is expected…
2022 American Transplant Congress
Acute Tubular Injury and Necrosis Do Not Lead to Meaningful Elevations in Donor-Derived Cell-Free DNA (dd-cfDNA)
S. R. Allam¹, M. Cooper², D. Kumar³, T. Maw⁴, A. Wiseman⁵, P. Chuang⁶, G. Shekhtman⁷, N. Agrawal⁷, J. Zeng⁷, E. Huang⁸
¹Medical City Transplant Institute, Fort Worth, TX, ²Medstar Georgetown Transplant Institute, Washington, DC, ³Virginia Commonwealth University, Richmond, VA, ⁴University of Southern California, Los Angeles, CA, ⁵Centura Health, Denver, CO, ⁶Metrolina Nephrology, Charlotte, NC, ⁷CareDx, Brisbane, CA, ⁸Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Associations between non-rejection histologic diagnoses and dd-cfDNA have not been extensively characterized. We explored these associations in kidney transplant recipients enrolled in the Kidney…
2022 American Transplant Congress
Real-Life Prevention of Breakthrough SARS-CoV-2 Infections by mRNA Vaccines in Kidney Transplant Recipients vs Hemodialysis Patients
D. Rodríguez-Espinosa, E. Montagud-Marrahi, J. Cacho, C. Arana, N. Taurizano, E. Hermida, J. Del Risco, J. Casals, A. Rosario, E. Cuadrado, N. Rodríguez, I. Revuelta, B. Bayès, P. Ventura-Aguiar, F. Cofan, E. Poch, F. Oppenheimer, M. Vera, L. Rodas, F. Maduell, F. Diekmann, A. Cases, J. Broseta, D. Cucchiari
Nephrology and Renal Transplantation, Hospital Clinic of Barcelona, Barcelona, Spain
*Purpose: The increased COVID-19 severity observed in kidney transplant recipients (KTR) has been widely reported. In addition, several studies have shown a reduced humoral and…
2022 American Transplant Congress
Kinetics of dd-cfDNA in Kidney Transplant Recipients Following Sars-CoV-2 Vaccination Booster Administration
N. M. Ali¹, S. Mehta¹, V. Tatapudi¹, A. Mattoo¹, I. Soomro¹, J. Benstein¹, H. Neumann¹, F. Zervou¹, J. Miles², R. Montgomery¹
¹Transplant Institute, NYU Langone Health, New York, NY, ²CareDx, Brisbane, CA
*Purpose: Evolving data suggests booster vaccine doses enhance the immunogenicity of SARS-CoV-2 vaccines in solid organ transplant recipients with higher IgG responses, neutralizing antibodies titers,…
2022 American Transplant Congress
A Randomized, Controlled, Double-blind Trial Of Inulin To Boost Response To A Third Covid-19 Vaccine Dose In Kidney Transplant Recipients.
J. Singer¹, M. Tunbridge², T. Salehi³, G. Perkins⁴, B. Grubnor-Bauk⁵, B. Sim³, T. Ying⁶, P. T. Coates³, S. J. Chadban¹
¹Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia, ²Renal Medicine, Royal Adelaide Hospital, Adelaide, Australia, ³Royal Adelaide Hospital, Adelaide, Australia, ⁴School of Biological Sciences, University of Adelaide, Adelaide, Australia, ⁵Adelaide University, Adelaide, Australia, ⁶Royal Prince Alfred Hospital, Sydney, Australia
*Purpose: Kidney transplant recipients (KTR) commonly exhibit inadequate responses to 2-dose COVID-19 vaccination schedules and remain at increased risk of severe COVID-19. Gut dysbiosis is…
2022 American Transplant Congress
Poor Prognosis of Proliferative Glomerulonephritis with Monoclonal IgG Deposits in Renal Allografts: A Retrospective Multicenter Study from China
Q. Wu¹, D. Liang¹, X. Ni¹, T. Song², X. Wu³, M. Zhang¹, J. Chen¹, D. Cheng¹, W. Jiqiu¹
¹National Clinical Research Center of Kidney Diseases, Jinling Hospital,Nanjing University Jinling School of Medicine, Nanjing, China, ²Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China, ³Department of Urology, Henan Provincial People's Hospital; Zhengzhou University People's Hospital, Zhengzhou, China
*Purpose: To analyze the clinicopathological characteristics, treatment efficacy and prognosis of proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) in renal allografts from multi-centers in China.*Methods:…
2022 American Transplant Congress
Center Variation is the Major Driver of Geographic Disparities in Access to Kidney Transplants Among Waitlisted Candidates
D. Stewart, A. Robinson, A. Wilk, D. Klassen
United Network for Organ Sharing, Richmond, VA
*Purpose: The OPTN’s monitoring of equity in access to deceased donor kidney (KI) transplants (tx) among waitlisted candidates has consistently found service area (DSA) of…
2022 American Transplant Congress
LGALS1 is Expressed in Glomerular Endothelial Cells and Induced Upon Stimulation with Anti-HLA Antibody
A. Boshart¹, S. Farkona¹, S. Clotet-Freixas¹, C. McEvoy¹, J. Murphy¹, S. Crome², A. Konvalinka³
¹Toronto General Hospital Research Institute, Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada, ²Immunology, Toronto General Hospital Research Institute, Ajmera Transplant Centre, University of Toronto, University Health Network, Toronto, ON, Canada, ³Nephrology, Toronto General Hospital Research Institute, Ajmera Transplant Centre, University Health Network, Toronto, ON, Canada
*Purpose: Antibody-mediated rejection (AMR) accounts for >50% of premature kidney graft loss. AMR is caused by donor specific antibodies (DSA) against human leukocyte antigens (HLA)…